As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

Cancer Discovery publishes high-impact articles featuring major advances in research and clinical trials. Topics span the spectrum of cancer research and medicine from the laboratory to the clinic to ...

Previous research has demonstrated that activin receptor-like kinase 7 (ALK7) signaling suppresses lipolysis, resulting in increased adipocyte size and lipid content. Additionally, predicted loss of ...

Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the appointment of Mikael Dolsten, M.D., Ph.D., former Chief Scientific O ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

Furthermore, co-treatment of tirzepatide, a GLP-1/GIP receptor co-agonist, with ALK7 siRNA enhanced the therapeutic benefits versus tirzepatide monotherapy, with additive effects on body weight ...

Arrowhead (ARWR) announced preclinical results on ARO-ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like ...

PASADENA, Calif. — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin ...

PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...